A phase 1 study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors.

被引：4
|
作者：
Hyman, David Michael
Brana, Irene
Spreafico, Anna
Schram, Alison M.
Pandya, Naimish B.
Hoffman, Kimberly
Hallet, Robin
Giblin, Patricia
Anido, Judit
Ruano, Isabel Huber
Wasserman, Robert
Magram, Jeanne
Siu, Lillian L.
Tabernero, Josep
Seoane, Joan
Baselga, Jose
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] UHN Princess Margaret Hosp, Cambridge, ON, Canada
[3] Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[5] Northern Biol Inc, Toronto, ON, Canada
[6] Vall dHebron Univ Hosp, Barcelona, Spain
[7] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS2602
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2602
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors
    Moreno, Victor
    Perets, Ruth
    Peretz-Yablonski, Tamar
    Fourneau, Nele
    Girgis, Suzette
    Guo, Yue
    Hellemans, Peter
    Verona, Raluca
    Pendas, Natalia
    Xia, Qi
    Geva, Ravit
    Calvo, Emiliano
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (01) : 93 - 104
  • [42] A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors
    Victor Moreno
    Ruth Perets
    Tamar Peretz-Yablonski
    Nele Fourneau
    Suzette Girgis
    Yue Guo
    Peter Hellemans
    Raluca Verona
    Natalia Pendás
    Qi Xia
    Ravit Geva
    Emiliano Calvo
    Investigational New Drugs, 2023, 41 : 93 - 104
  • [43] Dostarlimab Anti-PD-1 monoclonal antibody Treatment of advanced solid tumors
    Haddley, K.
    DRUGS OF THE FUTURE, 2019, 44 (07) : 527 - 534
  • [44] A phase 1/2 study of intermittent, high dose sunitinib in patients with advanced solid tumors.
    Rovithi, Maria
    Labots, Marlette
    Richard
    Honeywell
    Ten Tije, Albert J.
    Ruijter, Rita
    Skardhamar, Mikkjal
    Peters, Godefridus J.
    Voortman, Jens
    Verheul, Henk M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [45] A phase I study of TRC105 (anti-CD105 antibody) in patients with advanced solid tumors.
    Goldman, J. W.
    Gordon, M. S.
    Hurwitz, H.
    Pili, R.
    Mendelson, D. S.
    Adams, B. J.
    Alvarez, D.
    Seon, B. K.
    Theuer, C. P.
    Leigh, B. R.
    Rosen, L. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors
    Toshihiko Doi
    Takeshi Aramaki
    Hirofumi Yasui
    Kei Muro
    Masafumi Ikeda
    Takuji Okusaka
    Yoshitaka Inaba
    Kenya Nakai
    Hiroki Ikezawa
    Ryo Nakajima
    Investigational New Drugs, 2019, 37 : 1061 - 1074
  • [47] A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors
    Doi, Toshihiko
    Aramaki, Takeshi
    Yasui, Hirofumi
    Muro, Kei
    Ikeda, Masafumi
    Okusaka, Takuji
    Inaba, Yoshitaka
    Nakai, Kenya
    Ikezawa, Hiroki
    Nakajima, Ryo
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (05) : 1061 - 1074
  • [48] First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors
    Shitara, Kohei
    Uehai, Satoshi
    Shichino, Shigeyuki
    Aoki, Hiroyasu
    Ogiwara, Haru
    Nakatsura, Tetsuya
    Suzuki, Toshihiro
    Shimomura, Manami
    Yoshikawa, Toshiaki
    Shoda, Kayoko
    Kitano, Shigehisa
    Yamashita, Makiko
    Nakayama, Takayuki
    Sato, Akihiro
    Kuroda, Sakiko
    Wakabayashi, Masashi
    Nomura, Shogo
    Yokochi, Shoji
    Ito, Satoru
    Matsushima, Kouji
    Doi, Toshihiko
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 : 195
  • [49] AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors.
    Frentzas, Sophia
    Meniawy, Tarek
    Kao, Steven Chuan-Hao
    Wang, Ruihua
    Zuo, Yunxia
    Zheng, Hao
    Tan, Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors in Japan
    Boku, N.
    Yamazaki, K.
    Yamamoto, N.
    Takahashi, T.
    Fukutomi, A.
    Miyazaki, M.
    Satoh, T.
    Okamoto, I.
    Nakagawa, K.
    Fukuoka, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345